We are investigating the effects of Olaparib in patients with recurrent ovarian cancer who do not have BRCA mutations. The goal is to see if it helps maintain treatment benefits after initial therapy and to understand its safety and effectiveness.
Health conditions and diseases that the clinical trial is designed to study and treat.
Recurrent ovarian cancer is a type of cancer that returns after treatment. It occurs when cancer cells grow back in the ovaries or other areas after initial therapy, and it can happen in patients who do not have mutations in the BRCA 1 and 2 genes.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.